Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
Takashi KadowakiNobuya InagakiHirotaka WatadaKazuyo SasakiKazumi Mori-AnaiTomohisa IwasakiTatsuki TeranishiPublished in: Advances in therapy (2022)
JapicCTI-173778.